stoxline Quote Chart Rank Option Currency Glossary
  
Relmada Therapeutics, Inc. (RLMD)
3.03  0.03 (1%)    06-18 16:00
Open: 3
High: 3.19
Volume: 88,854
  
Pre. Close: 3
Low: 2.99
Market Cap: 91(M)
Technical analysis
2024-06-18 4:48:34 PM
Short term     
Mid term     
Targets 6-month :  3.79 1-year :  4.38
Resists First :  3.25 Second :  3.75
Pivot price 3.01
Supports First :  2.45 Second :  2.03
MAs MA(5) :  3.01 MA(20) :  3.03
MA(100) :  4.41 MA(250) :  3.56
MACD MACD :  -0.2 Signal :  -0.3
%K %D K(14,3) :  71.3 D(3) :  70.8
RSI RSI(14): 39.8
52-week High :  7.22 Low :  2.35
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ RLMD ] has closed below upper band by 41.2%. Bollinger Bands are 85% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.19 - 3.22 3.22 - 3.23
Low: 2.95 - 2.97 2.97 - 2.99
Close: 3 - 3.04 3.04 - 3.06
Company Description

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Headline News

Tue, 18 Jun 2024
Relmada Therapeutics publishes results of depression drug trial - Green Market Report

Tue, 18 Jun 2024
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The ... - StockTitan

Tue, 18 Jun 2024
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The ... - Yahoo Finance

Sat, 15 Jun 2024
Opaleye Management Inc. Purchases 847,000 Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) - MarketBeat

Sat, 11 May 2024
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call Transcript - Insider Monkey

Thu, 21 Mar 2024
Relmada Therapeutics: Run Up Into Results May Resume Following This Drop (NASDAQ:RLMD) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 30 (M)
Shares Float 28 (M)
Held by Insiders 8 (%)
Held by Institutions 49.3 (%)
Shares Short 1,570 (K)
Shares Short P.Month 1,710 (K)
Stock Financials
EPS -3.14
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.39
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -56 %
Return on Equity (ttm) -95.5 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -48 (M)
Levered Free Cash Flow -16 (M)
Stock Valuations
PE Ratio -0.97
PEG Ratio 0
Price to Book value 1.26
Price to Sales 0
Price to Cash Flow -1.9
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android